N/A N=48 Treatment

An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery

Morbid Obesity

Bottom Line

View on ClinicalTrials.gov: NCT02067585 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcome: Primary: Triglycerides Post-prandial — 95; 71; 134 mmol/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Standardized Lipid meals (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Alberta
Primary completion: Aug 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Triglycerides Post-prandial	95; 71; 134	—
PRIMARY Triglycerides	93; 85; 115	—
PRIMARY Triglyceride	103; 59; 123	—
PRIMARY Triglyceride	103; 59; 123	—
PRIMARY Triglyceride	103; 59; 123	—
SECONDARY Blood Glucose	4.8; 4.7; 5.5	—
SECONDARY Glucose	4.8; 4.7; 4.9	—
SECONDARY Glucose	4.8; 4.7; 4.9	—
SECONDARY Glucose	4.8; 4.7; 4.9	—
SECONDARY Glucose	4.8; 4.7; 4.9	—

Summary

Bariatric surgery induce remarkable weight loss and improvement or resolution of type 2 diabetes. Obesity is the primary risk factor for type 2 diabetes, and 90% of all type 2 diabetics are obese. Type 2 diabetes resolves post-operatively in 84-98% after bypass and 48-68% after restrictive procedures. Obesity leads to elevated plasma free fatty acids and subsequently to excessive accumulation of triglyceride in peripheral tissues, which is an independent risk factor for insulin resistance and type 2 diabetes. Bariatric surgery is associated with dramatic decrease in plasma free fatty acids and other lipids. This study will clarify the relationship of changes in fatty acid and other lipid metabolism to improved insulin sensitivity after different bariatric procedures ('restrictive' - laparoscopic adjustable gastric band and 'hybrid' - laparoscopic roux-en-y gastric bypass) and compare them with non-surgical obese patients. This will allow the investigators to refine indications for these procedures especially in patients with type 2 diabetes. The investigators will analyze whether surgical bypass of the upper small bowel plays a critical role in the resolution of type 2 diabetes and improvement in lipid metabolism. The investigators will achieve this by comparing gastric banding and gastric bypass in a collaborative research study involving obesity surgeons, physicians and lipid researchers.

Eligibility Criteria

Inclusion Criteria

morbidly obese patients
age 18-65
with or without type 2 diabetes
12 or more months following LRYGB or LAGB, or patients waiting for mentioned procedures
able to provide written informed consent.

Exclusion Criteria

chronic liver disease
maladaptive eating behavior
current pharmacological treatment for obesity
for patients following LAGB - ongoing band volume adjustments
hypothyroidism
treatment with insulin
revision of a previous bariatric procedure
major postoperative complication
allergy to soy or any component of the study meal
renal failure (glomerular filtration <60mL/min)
alcoholism
acute illness
pregnancy or nursing.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02067585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.